Gardasil Short Course (HPV)

£5.50

This is part of the ‘Health Academy Short Course’ series and provides clinicians with specific information related to the Gardasil vaccine.

This course is suitable for all Registered Healthcare Professionals, including Nurses, Pharmacists and GPs that administer this vaccine in practice.

This ‘Short Course’ will take approximately 15 minutes to complete.

Description

This is part of the ‘Health Academy Short Course’ series and provides clinicians with specific information related to the Gardasil vaccine.

This course is suitable for all Registered Healthcare Professionals, including Nurses, Pharmacists and GPs that administer this vaccine in practice.

This ‘Short Course’ will take approximately 15 minutes to complete.

 

The course will cover key details of the vaccine and the diseases that it protects against.

 

What Gardasil is and what it is used for
Gardasil is a vaccine. Vaccination with Gardasil is intended to protect against diseases caused by
Human Papillomavirus (HPV) types 6, 11, 16, and 18.

These diseases include pre-cancerous lesions of the female genitals (cervix, vulva, and vagina); precancerous lesions of the anus and genital warts in males and females; cervical and anal cancers. HPV
types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal
cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina, 75% of HPV related
pre-cancerous lesions of the anus. HPV types 6 and 11 are responsible for approximately 90% of
genital wart cases.

Gardasil is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases.

Gardasil does not have any effect in individuals who already have a persistent infection or disease
associated with any of the HPV types in the vaccine. However, in individuals who are already infected
with one or more of the vaccine HPV types, Gardasil can still protect against diseases associated with
the other HPV types in the vaccine.

Gardasil cannot cause the diseases it protects against.

Gardasil produces type-specific antibodies and has been shown in clinical trials to prevent HPV 6-,
11-, 16-, and 18-related diseases in women 16-45 years of age and in men 16-26 years of age. The
vaccine also produces type-specific antibodies in 9- to 15-year-old children and adolescents.

Reviews

There are no reviews yet.

Be the first to review “Gardasil Short Course (HPV)”

Your email address will not be published. Required fields are marked *